BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28395975)

  • 1. Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155.
    Takahashi N; Sugaya M; Suga H; Oka T; Kawaguchi M; Miyagaki T; Fujita H; Inozume T; Sato S
    J Invest Dermatol; 2017 Aug; 137(8):1766-1773. PubMed ID: 28395975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
    Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
    Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells.
    Gong J; Fang L; Liu R; Wang Y; Xing J; Chen Y; Zhuang R; Zhang Y; Zhang C; Yang A; Zhang X; Jin B; Chen L
    Eur J Immunol; 2014 Dec; 44(12):3758-67. PubMed ID: 25209846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155/CD226-interaction impacts on the generation of innate CD8(+) thymocytes by regulating iNKT-cell differentiation.
    Georgiev H; Ravens I; Shibuya A; Förster R; Bernhardt G
    Eur J Immunol; 2016 Apr; 46(4):993-1003. PubMed ID: 26689152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.
    Seth S; Qiu Q; Danisch S; Maier MK; Braun A; Ravens I; Czeloth N; Hyde R; Dittrich-Breiholz O; Förster R; Bernhardt G
    J Biol Chem; 2011 Nov; 286(45):39153-63. PubMed ID: 21937446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
    Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
    Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells.
    Seth S; Georgoudaki AM; Chambers BJ; Qiu Q; Kremmer E; Maier MK; Czeloth N; Ravens I; Foerster R; Bernhardt G
    J Leukoc Biol; 2009 Jul; 86(1):91-101. PubMed ID: 19380711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD226 interaction with CD155 impacts on retention and negative selection of CD8 positive thymocytes as well as T cell differentiation to follicular helper cells in Peyer's Patches.
    Danisch S; Qiu Q; Seth S; Ravens I; Dorsch M; Shibuya A; Shibuya K; Förster R; Bernhardt G
    Immunobiology; 2013 Feb; 218(2):152-8. PubMed ID: 22429743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
    Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
    Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
    Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
    Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.
    Wang H; Qi J; Zhang S; Li Y; Tan S; Gao GF
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):988-996. PubMed ID: 30591568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1.
    Du X; de Almeida P; Manieri N; de Almeida Nagata D; Wu TD; Harden Bowles K; Arumugam V; Schartner J; Cubas R; Mittman S; Javinal V; Anderson KR; Warming S; Grogan JL; Chiang EY
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11731-E11740. PubMed ID: 30504141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking CD226 Promotes Allogeneic Transplant Immune Tolerance and Improves Skin Graft Survival by Increasing the Frequency of Regulatory T Cells in a Murine Model.
    Liu T; Zhang D; Zhang Y; Xu X; Zhou B; Fang L; Zhang Y; Su Y; Jin B; Zhuang R; Guo S
    Cell Physiol Biochem; 2018; 45(6):2338-2350. PubMed ID: 29550821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD155, an onco-immunologic molecule in human tumors.
    Gao J; Zheng Q; Xin N; Wang W; Zhao C
    Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
    Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
    Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma.
    Asadullah K; Friedrich M; Döcke WD; Jahn S; Volk HD; Sterry W
    J Invest Dermatol; 1997 May; 108(5):743-7. PubMed ID: 9129226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor intrinsic and extrinsic immune functions of CD155.
    O'Donnell JS; Madore J; Li XY; Smyth MJ
    Semin Cancer Biol; 2020 Oct; 65():189-196. PubMed ID: 31883911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
    Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
    Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.